Eisai Co., Ltd. (Headquarters: Tokyo, President: Haruo Naito) announced that its UK subsidiary, Eisai Ltd. (Headquarters: London, Managing Director: Paul Hooper) has received notice on July 7 of approval through a Mutual Recognition Procedure in Europe for PARIET (rabeprazole sodium), a proton pump inhibitor, for the treatment of Zollinger-Ellison syndrome (ZES). A type II variation for the compound had been submitted through the MHRA on December 11, 2003.
In ZES, high levels of gastrin secretion from tumors in the pancreas or the small intestine lead to increased gastric acid levels, which results in multiple gastric ulcers. PARIET has already been approved for the treatment of ZES in Japan and in the United States under the brand name ACIPHEX .
PARIET was launched in the EU in 1998. Eisai's marketing subsidiaries market PARIET in the United Kingdom and Germany. Janssen-Cilag markets the product in the other European countries. PARIET was first launched in 1997 in Japan, and it was launched as ACIPHEX in 1999 in the United States. Currently, the product has been launched in 72 countries worldwide.
Since its establishment, Eisai has been committed to developing drugs for the treatment of gastrointestinal diseases. The company hopes to contribute further to the treatment of acid-related diseases.
Eisai Co., Ltd.
Corporate Communications Department